Anika Therapeutics, Inc. (NASDAQ:ANIK)

SteadySaber (76.58) Submitted: 6/8/2007 5:04:37 PM : Start Price: $15.45 ANIK Score: -4.31

New products second half. P/E looks high. Any room to make some money?

This year's earnings trade at a 29 p/e for .51 est. With a ttm p/e of 36. So lets say they hit the numbers and get .51. That should imply an $18 stock based on the ttm p/e of 36. It woud seem 36 is pretty high and I would bet the TTM goes down more than up. So 20% upside doesn't give much room for comfort if we look at backwards p/e.

New things are coming so maybe forward p/e is the better metric. Say they hit .51 and the following years est. is .79 according to the analysts right now. Based on the current forward p/e of 29 (off of the .51 est) gets you a $22 stock on .79 after they hit the .51 numbers. So there you have it - this stock should trade between 18 and 22 by the end of the fiscal year. More likely 22. That's assuming the new products will really generate the growth that this p/e imply.

For the risk assumed about the new products, investors can expect a tiddy 46% profit if it paysoff.

1ct (33.74) Submitted: 6/6/2007 2:05:44 PM : Start Price: $15.21 ANIK Score: -2.29

ANIK has the "gorilla" marketing partner, JNJ (Johnson and Johnson)to make it very successful for strong deployment of "orthovisc" throughout U.S. and international. "Elevess", new product just now being deployed with Galderma, should begin to take hold for 3rd quarter. New products, higher sales, should equate to much higher eps and stock price. Technically excellent formations for accumulation ongoing makes ANIK very attractive.

fusgeyer (< 20) Submitted: 4/27/2007 10:49:07 AM : Start Price: $13.90 ANIK Score: +4.33

Earnings are great, they have received approvals for new drugs and the US sales of their new orthopedic treatment is expected to be very strong.

henncoop (96.77) Submitted: 4/16/2007 2:03:46 AM : Start Price: $14.12 ANIK Score: +0.76

approval of comestic filler for use in Europe should add to revenue ... been watching it a while just wished I'd bought it earlier

kem29575 (51.38) Submitted: 4/10/2007 10:09:36 AM : Start Price: $13.40 ANIK Score: +5.13

it's a major growth sector

RandomGuy123 (68.41) Submitted: 2/8/2007 7:39:19 AM : Start Price: $13.17 ANIK Score: +6.65

Check out Wall Street Mayhem for the pitch. This company looks great, and recently the FDA approved their cheaper version of Botox.

salvatore85 (< 20) Submitted: 2/1/2007 9:16:59 PM : Start Price: $13.31 ANIK Score: +5.52

The high yield, and the low P/E ratio compared to its competitors. The past company performance and its good PEG ratio.

ajb102 (< 20) Submitted: 12/15/2006 12:22:53 PM : Start Price: $13.50 ANIK Score: +2.92

Orthovisc just got separate medicare code making utilization easier.

NobodezFool (91.06) Submitted: 12/12/2006 12:14:14 PM : Start Price: $12.30 ANIK Score: +11.45

PEG .96
Cash Flow
Growth
Positive Earnings Surprises
Am I missing something? Why such little interest in this company? Maybe someone with better analysis skills can explain the lackluster stock performance for me. I see no reason why this should not be trading at $15-$16.

Stazita (< 20) Submitted: 11/28/2006 10:15:36 PM : Start Price: $13.69 ANIK Score: -0.91

Growing

5STARsmallCAPS (78.14) Submitted: 11/24/2006 1:02:25 PM : Start Price: $11.87 ANIK Score: +14.49

5-star $126 million market cap on 11/24/06
Products for tissue healing and protection, including OrthoVisc.
5STARsmallCAPS picks five star stocks with the smallest market caps.

Zikar (< 20) Submitted: 11/17/2006 1:38:10 PM : Start Price: $11.58 ANIK Score: +17.47

Osteoarthritis medicines will only increase in demand as the population ages. Profitable, with strong growth make this a buy!